We hypothesized that our strategy of temporal modulation of the membrane bioavailability and stability of HER2 by treatment with lovastatin could extend the benefits of pretargeted immuno-PET to this class of rapidly internalizing tumor-associated antigens (Fig. 5). The gene discussed is ERBB2; the disease is neoplasm.